There is no experience with acute overdose of ZOMIG. Clinical study subjects who received single 50 mg oral doses of ZOMIG commonly experienced sedation.

There is no specific antidote to ZOMIG. In cases of severe intoxication, intensive care procedures are recommended, including establishing and maintaining a patent airway, ensuring adequate oxygenation and ventilation, and monitoring and support of the cardiovascular system.

The elimination half-life of ZOMIG is 3 hours [see CLINICAL PHARMACOLOGY]; therefore, monitor patients after overdose with ZOMIG for at least 15 hours or until symptoms or signs resolve. It is unknown what effect hemodialysis or peritoneal dialysis has on the plasma concentrations of zolmitriptan.

ZOMIG is contraindicated in patients with:

• Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), other significant underlying cardiovascular disease, or coronary artery vasospasm including Prinzmetal's angina [see WARNINGS AND PRECAUTIONS]
• Wolff-Parkinson-White Syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see WARNINGS AND PRECAUTIONS]
• History of stroke, transient ischemic attack (TIA), or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [see WARNINGS AND PRECAUTIONS]
• Peripheral vascular disease (PVD) [see WARNINGS AND PRECAUTIONS]
• Ischemic bowel disease [see WARNINGS AND PRECAUTIONS]
• Uncontrolled hypertension [see WARNINGS AND PRECAUTIONS]
• Recent use (i.e., within 24 hours) of another 5-HT1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see DRUG INTERACTIONS]
• Concurrent administration of a monoamine oxidase (MAO)-A inhibitor or recent use of a MAO-A inhibitor (that is within 2 weeks) [see DRUG INTERACTIONS and CLINICAL PHARMACOLOGY]
• Known hypersensitivity to ZOMIG or ZOMIG ZMT (angioedema and anaphylaxis seen) [see ADVERSE REACTIONS]

Last reviewed on RxList: 10/1/2012
This monograph has been modified to include the generic and brand name in many instances.